Related Experiment Videos
Is neoadjuvant hormonal therapy before radical prostatectomy indicated?
1Division of Urologic Surgery, Section of Urologic Oncology, University of North Carolina, School of Medicine, Chapel Hill, NC 27599-7235, USA.
Urologia Internationalis
|May 22, 2004
Summary
Neoadjuvant hormonal therapy (NHT) before radical prostatectomy does not improve disease-free survival for prostate cancer patients. Its routine use is not recommended outside of controlled investigational trials due to uncertain benefits and significant costs.
Area of Science:
- Urology
- Oncology
- Surgical Oncology
Background:
- Radical prostatectomy is a primary treatment for organ-confined prostate cancer.
- Nearly 50% of patients are upstaged after surgery, indicating limitations of current treatment.
- Neoadjuvant hormonal therapy (NHT) is explored to improve surgical outcomes.
Purpose of the Study:
- To review the efficacy of NHT prior to radical prostatectomy.
- To discuss the impact of NHT on pathological staging and surgical outcomes.
Main Methods:
- Comprehensive literature review focusing on prospective, randomized trials of NHT.
- Inclusion of other relevant texts and journal articles on hormonal therapy's effects.
- Analysis of histopathological evaluations and patient outcomes.
Main Results:
- No clear evidence shows NHT improves disease-free survival across prostate cancer stages.
- A potential reduction in positive surgical margins for T2 disease lacks confirmed significance.
- NHT is associated with increased financial costs, patient morbidity, and surgical complexity.
Conclusions:
- Routine neoadjuvant hormonal therapy before radical prostatectomy is not currently justified.
- Consideration of NHT should be limited to controlled investigational settings.
- Further research is needed to clarify the role, if any, of NHT in prostate cancer management.